Investor Relations

About Vivani

Vivani Medical is an emerging biopharmaceutical company developing a pipeline of miniature, long-term drug implants with its proprietary NanoPortal™ platform technology for obesity/weight management and other chronic diseases.

Vivani’s lead drug implant candidates are designed to improve medication adherence and deliver smooth consistent therapeutic levels of GLP-1 – the same class of active pharmaceutical ingredients in Ozempic®, Trulicity® and Wegovy® – for six months or longer with a single administration. NPM-115 and NPM-119, are miniature, six-month, GLP-1 (exenatide) implants under development for chronic weight management obesity and type 2 diabetes, respectively.

As a result of positive preclinical weight loss data comparing NPM-115 to Ozempic/Wegovy and the transformational change in the obesity market, Vivani has decided to prioritize development of its obesity portfolio moving forward which also includes NPM-139 (semaglutide implant) with the potential for once-yearly dosing.

Vivani continues to proceed towards initiating LIBERATE-1, a First-in-Human (FIH) study assessing NPM-119’s safety and pharmacokinetic profile in type 2 diabetes patients. In addition to an active control arm with Bydureon BCise®, LIBERATE-1 will also assess NPM-119’s effect on both glycemic control and weight.

NanoPortal™ has broad potential application across a range of molecule types including peptide therapeutics.

Latest Presentation

2024 Investor Presentation

Latest Financial Results

Q1 2024

Quarter Ended March 31, 2024

Latest Annual Filing

For Fiscal Year Ending December 31, 2023

Stock Snapshot

IR Contacts

Company

Vivani Medical, Inc.
1350 S. Loop Road
Alameda, CA 94502
United States
T: 415-506-8462

Investor Relations

Brigid Makes
Chief Financial Officer
T: 415-506-8462
investors@vivani.com

Transfer Agent

Vstock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436